Clinical Trials Browser

INDUSTRY × selinexor × Clear all

NCT06158841 2026-05-27

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07569757 2026-05-08

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Phase 3 Not yet recruiting

Multiple Myeloma

NCT02227251 2026-05-06

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Active not recruiting

244 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02343042 2026-05-04

STOMP

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05611931 2026-04-23

XPORT-EC-042

Phase 3 Recruiting

Endometrial Neoplasms

NCT03555422 2026-04-13

ENGOT-EN5

Phase 3 Completed

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT04562389 2026-04-09

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT05954780 2026-01-14

SEATTLE

Active not recruiting

Multiple Myeloma

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05265975 2025-06-09

SWATCH

Phase 1/2 Terminated

Lymphoma, Large B-Cell, Diffuse

NCT04256707 2025-03-19

SPRINT

Phase 1/2 Completed

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03992339 2025-02-07

SEARCH

Phase 2 Completed

60 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT06225310 2025-01-16

KPT-IST-391

Phase 1 Recruiting

Multiple Myeloma

NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Phase 1/2 Terminated

74 enrolled 23 charts

Glioblastoma

NCT04768881 2024-08-23

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Phase 2 Terminated

15 enrolled 15 charts

Melanoma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT01896505 2024-01-08

A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma

Phase 1 Completed

54 enrolled 28 charts

Bone Neoplasms, Sarcoma

NCT04854434 2023-11-03

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Phase 2 Terminated

13 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT04519476 2023-10-31

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Phase 1 Unknown

Multiple Myeloma

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Phase 1 Completed

192 enrolled 29 charts

CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

NCT01986348 2023-01-26

KING

Phase 2 Terminated

76 enrolled 16 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT02025985 2023-01-26

SIGN

Phase 2 Completed

116 enrolled 21 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02088541 2023-01-26

SOPRA

Phase 2 Completed

317 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02138786 2023-01-26

SIRRT

Phase 2 Terminated

27 enrolled 17 charts

Richter's Transformation

NCT02146833 2023-01-26

SHIP

Phase 2 Terminated

20 enrolled 13 charts

Prostatic Neoplasms

NCT02213133 2023-01-26

STARRS

Phase 2 Terminated

45 enrolled 12 charts

Carcinoma, Carcinoma, Squamous Cell

NCT02314247 2023-01-26

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Phase 2 Terminated

16 enrolled 16 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02628704 2023-01-26

SCORE

Phase 2 Withdrawn

Multiple Myeloma

NCT02606461 2023-01-23

SEAL

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma